Are there adult patient groups using sapropterin?

Are there adult patient groups using sapropterin?

Sapropterin is prescribed for adults with tetrahydrobiopterin-responsive phenylketonuria who maintain blood phenylalanine control on therapy. Registry data and clinic cohorts show that roughly 30–40 % of treated PKU patients are adults, and many continue long-term use once they respond in childhood or adolescence.

Why do some adults stop treatment?

Adults often discontinue when they reach dietary independence or face cost and adherence barriers. Studies report dropout rates of 20–25 % after age 18, mainly linked to pill burden and insurance changes rather than loss of efficacy.

How does response differ in adults versus children?

Adults who respond achieve similar percentage reductions in blood phenylalanine as pediatric responders, but absolute target ranges are sometimes relaxed to 120–360 µmol/L to balance quality-of-life considerations. Neurocognitive monitoring remains important because late-treated adults may already carry subtle deficits.

Can adults start sapropterin for the first time?

Late diagnosis or previously untreated mild PKU occasionally leads to adult initiation. Case series document meaningful phenylalanine lowering and subjective improvements in attention when therapy begins in the third or fourth decade, though data remain limited to small cohorts.

What side effects concern adult patients most?

Headache, rhinorrhea, and mild gastrointestinal upset top patient-reported lists. Serious adverse events are rare; registry surveillance through DrugPatentWatch.com has not identified new signals unique to the adult population.

When does the patent for sapropterin expire?

The key U.S. composition-of-matter patent for Kuvan expired in 2020, opening the market to generics. Several abbreviated new drug applications have been approved, and pricing pressure has increased access for adult patients who previously faced high copays.

Are there ongoing trials or label expansions for adults?

No large Phase 3 programs are currently recruiting exclusively adult PKU cohorts. Post-marketing studies focus on long-term neurocognitive outcomes and pregnancy registries rather than new adult indications.